Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787267 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00787267 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 37 participants.
The verdict
NCT00787267, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that has progressed after previous therapy. Safety and response to dasatinib will be assessed. Fresh frozen tumor tissue must be available for genomics analysis prior to initiating dasatinib therapy. A biopsy must be obtained after any prior chemotherapy. If fresh frozen tumor tissue is not available, a biopsy will be required to participate in this trial.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787267
The ClinicalTrials.gov registry entry for NCT00787267 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00787267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787267 about?
NCT00787267 is a clinical study titled "Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC". On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that has progressed after previous therapy. Safety and response to dasatinib will be assessed. Fresh frozen tumor tissue must be available for genomics analysis prior to initiating dasatinib therapy. A biopsy must...
What is the current status of trial NCT00787267?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2008-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00787267?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00787267?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.